Core Points - Phathom Pharmaceuticals, Inc. will host a live webcast on October 30, 2025, at 8:00 am EDT to report its third quarter 2025 financial results and provide a business update [1] - The webcast will be accessible through the Events & Presentations section of the Phathom website, with a recording available for 90 days post-call [2] Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada [3] - Phathom markets vonoprazan in the U.S. as VOQUEZNA® for various gastrointestinal conditions, including heartburn relief and H. pylori infection treatment [3]

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Phathom's commercialization plans. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom's business, including, without limitation: ...

Core Insights - Phathom Pharmaceuticals has appointed Ted Schroeder to its Board of Directors, which is seen as a strategic move during a critical time for the company [1][3]. Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases, including the first-in-class potassium-competitive acid blocker (PCAB) vonoprazan, marketed as VOQUEZNA® [7]. Leadership Experience - Ted Schroeder brings over 30 years of experience in the biopharmaceutical industry, having held leadership roles in various companies and successfully guiding them through significant milestones and transactions [2][4]. - His previous roles include CEO of Nabriva Therapeutics and co-founder of Cadence Pharmaceuticals, which was acquired for $1.4 billion [4]. Strategic Importance - The appointment of Schroeder is expected to enhance Phathom's operational and commercial capabilities, particularly as the company aims to accelerate its commercial momentum and deliver innovative therapies to patients [3][5].

Core Viewpoint - Phathom Pharmaceuticals has appointed Steven Basta as the new President and CEO, succeeding Terrie Curran, to lead the company during a critical growth phase focused on expanding the commercial potential of its gastrointestinal treatments, particularly VOQUEZNA [1][2]. Company Overview - Phathom Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for gastrointestinal diseases, with a focus on the potassium-competitive acid blocker, vonoprazan, marketed as VOQUEZNA [5]. Leadership Transition - Steven Basta brings over 25 years of experience in the biopharmaceutical and medical device industries, having previously served as CEO at various companies, including SaNOtize and Mahana Therapeutics [3][4]. - Terrie Curran, the former CEO, expressed pride in the company's achievements over the past five years and confidence in its future growth potential [2]. Strategic Focus - The Board of Directors aims to accelerate commercial growth and enhance shareholder value under Basta's leadership, leveraging his extensive experience in product development and commercial strategy [2][3]. - Basta emphasized the need for innovative treatment options in the gastrointestinal market and Phathom's unique position to capture significant opportunities [2].